KR20150010973A - 피라졸 유도체 및 lpar5 길항제로서의 그의 용도 - Google Patents

피라졸 유도체 및 lpar5 길항제로서의 그의 용도 Download PDF

Info

Publication number
KR20150010973A
KR20150010973A KR20147033843A KR20147033843A KR20150010973A KR 20150010973 A KR20150010973 A KR 20150010973A KR 20147033843 A KR20147033843 A KR 20147033843A KR 20147033843 A KR20147033843 A KR 20147033843A KR 20150010973 A KR20150010973 A KR 20150010973A
Authority
KR
South Korea
Prior art keywords
alkyl
group
phenyl
methyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20147033843A
Other languages
English (en)
Korean (ko)
Inventor
마르크 나자레
데틀레프 코지안
안드레아스 에베르스
베른가르트 체흐티즈키
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20150010973A publication Critical patent/KR20150010973A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR20147033843A 2012-05-18 2013-05-16 피라졸 유도체 및 lpar5 길항제로서의 그의 용도 Ceased KR20150010973A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305552 2012-05-18
EP12305552.7 2012-05-18
PCT/EP2013/060171 WO2013171317A1 (en) 2012-05-18 2013-05-16 Pyrazole derivatives and their use as lpar5 antagonists

Publications (1)

Publication Number Publication Date
KR20150010973A true KR20150010973A (ko) 2015-01-29

Family

ID=48446368

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147033843A Ceased KR20150010973A (ko) 2012-05-18 2013-05-16 피라졸 유도체 및 lpar5 길항제로서의 그의 용도

Country Status (22)

Country Link
US (1) US9346762B2 (cg-RX-API-DMAC7.html)
EP (1) EP2882715B1 (cg-RX-API-DMAC7.html)
JP (1) JP6257596B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150010973A (cg-RX-API-DMAC7.html)
CN (1) CN104302625B (cg-RX-API-DMAC7.html)
AU (1) AU2013261718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014028406A2 (cg-RX-API-DMAC7.html)
CA (1) CA2871542A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118618T1 (cg-RX-API-DMAC7.html)
DK (1) DK2882715T3 (cg-RX-API-DMAC7.html)
ES (1) ES2612205T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170098T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032890T2 (cg-RX-API-DMAC7.html)
IL (1) IL235221A (cg-RX-API-DMAC7.html)
LT (1) LT2882715T (cg-RX-API-DMAC7.html)
MX (1) MX347615B (cg-RX-API-DMAC7.html)
PL (1) PL2882715T3 (cg-RX-API-DMAC7.html)
PT (1) PT2882715T (cg-RX-API-DMAC7.html)
RU (1) RU2645344C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201407210SA (cg-RX-API-DMAC7.html)
SI (1) SI2882715T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013171317A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
AU2016277126A1 (en) * 2015-06-12 2017-12-14 Vettore, LLC MCT4 inhibitors for treating disease
BR112019011825A2 (pt) 2016-12-12 2019-10-22 Vettore, LLC composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente
KR20220077140A (ko) 2019-10-02 2022-06-08 도메인 테라퓨틱스 프로스타글란딘 e2(pge2) ep4 수용체 길항제
WO2024092205A1 (en) * 2022-10-27 2024-05-02 The Trustees Of Indiana University Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease
CN119930520B (zh) * 2023-11-03 2026-03-06 中国药科大学 N-芳基吡唑类化合物及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
US7279478B2 (en) 2002-09-04 2007-10-09 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
AU2010224652A1 (en) * 2009-03-19 2011-10-13 Sanofi Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof
BR112012002130A2 (pt) * 2009-08-03 2015-09-15 Aziende Chimique Riunite Angelini Francesco A C R A F S P A processo para a preparação de composto,e, composto intermediário
JP6039559B2 (ja) * 2010-09-02 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Lpa受容体アンタゴニストとしてのピラゾロピリジノン誘導体
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用

Also Published As

Publication number Publication date
EP2882715A1 (en) 2015-06-17
MX2014014011A (es) 2015-02-12
RU2014151360A (ru) 2016-07-10
AU2013261718A1 (en) 2014-12-18
CN104302625B (zh) 2017-04-19
BR112014028406A2 (pt) 2017-06-27
CN104302625A (zh) 2015-01-21
CY1118618T1 (el) 2017-07-12
US9346762B2 (en) 2016-05-24
AU2013261718B2 (en) 2017-10-19
WO2013171317A1 (en) 2013-11-21
HUE032890T2 (hu) 2017-11-28
PL2882715T3 (pl) 2017-04-28
LT2882715T (lt) 2017-02-10
PT2882715T (pt) 2016-12-30
RU2645344C2 (ru) 2018-02-21
JP2015517514A (ja) 2015-06-22
IL235221A (en) 2016-06-30
CA2871542A1 (en) 2013-11-21
US20150141477A1 (en) 2015-05-21
HRP20170098T1 (hr) 2017-03-24
JP6257596B2 (ja) 2018-01-10
MX347615B (es) 2017-05-04
SI2882715T1 (sl) 2017-03-31
DK2882715T3 (en) 2017-02-13
EP2882715B1 (en) 2016-11-09
ES2612205T3 (es) 2017-05-12
SG11201407210SA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
CN116082303B (zh) 新型氧代吡啶类化合物及其中间体和应用
JP6884801B2 (ja) 血漿カリクレインインヒビターとしてのピラゾール誘導体
CN102239164A (zh) 2h-色烯化合物及其衍生物
KR20170090451A (ko) 혈장 칼리크레인의 저해제로서의 n-((het)아릴메틸)-헤테로아릴-카르복사미드 화합물
HK1214247A1 (zh) 作為細胞凋亡信號調節激酶抑制劑的經取代的吡啶-2-甲酰胺化合物
EA015942B1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
CN110101700A (zh) 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
AU2013261718B2 (en) Pyrazole derivatives and their use as LPAR5 antagonists
KR102947730B1 (ko) 염증성 기도 질환의 치료를 위한 오토탁신 (atx) 조절제로서의 1-(6-(메톡시)피리다진-3-일)사이클로프로판-1-카르복사미드 유도체
CN105209440B (zh) 作为凝血酶抑制剂的卤代吡唑
JP2022527618A (ja) Trpc6阻害剤
EP2850062B1 (en) Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
CN112778273B (zh) 环酮并吡啶酮类化合物及其制备方法和用途
KR20150016304A (ko) 벤조[1,3]디옥신 유도체 및 lpar5 길항제로서의 그의 용도
TW202235078A (zh) 自分泌運動因子(autotaxin)之新穎的抑制劑
JP2011503022A (ja) レニン阻害剤としての4,4−二置換ピペリジン
JP7458984B2 (ja) テトラヒドロイソキノリン系誘導体、その製造方法及び用途
WO2019144811A1 (zh) 四氢异喹啉类衍生物及其制备方法和用途
HK40035558A (en) Aromatic sulfonamide derivatives for the treatment of ischemic stroke
JP2006516127A (ja) ホスホジエステラーゼ4阻害剤としてのフタラジン誘導体
KR20130131775A (ko) 인자 XIa 억제 활성을 갖는 다이펩타이드 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180516

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190812

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191022

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190812

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I